Haley D Heibel1, Aleksi J Hendricks2, James P Foshee3, Vivian Y Shi3. 1. School of Medicine, Creighton University, Omaha, NE, USA. 2. College of Medicine, University of Arizona, Tucson, AZ, USA. 3. Department of Medicine, Division of Dermatology, University of Arizona, Tucson, AZ, USA.
Abstract
Background: Dupilumab is used for treatment of atopic dermatitis through blockade of IL-4 and IL-13 signaling of the Th2 pathway. Recent case reports have described alopecia, psoriasis, persistent facial dermatitis, and recall dermatitis at patch test sites after the initiation of dupilumab therapy.Case report: We describe the case of a 67-year-old female with atopic dermatitis who developed recurrent episodic flares of rosacea temporally associated with dupilumab injections that resolved after dupilumab discontinuation. Conclusion: The cause of rosacea-like reaction associated with dupilumab treatment is unknown. Th2 pathway inhibition by dupilumab may promote Demodex proliferation and increased IL-17-mediated inflammation implicated in the pathophysiology of rosacea.Abbreviations: atopic dermatitis: AD; interleukin: IL; persistent facial dermatitis: PFD; T-helper cell type 1: Th1; T-helper cell type 2: Th2; T-helper cell type 17: Th17; tumor necrosis factor-∝: TNF-∝.
Background: Dupilumab is used for treatment of atopic dermatitis through blockade of IL-4 and IL-13 signaling of the Th2 pathway. Recent case reports have described alopecia, psoriasis, persistent facial dermatitis, and recall dermatitis at patch test sites after the initiation of dupilumab therapy.Case report: We describe the case of a 67-year-old female with atopic dermatitis who developed recurrent episodic flares of rosacea temporally associated with dupilumab injections that resolved after dupilumab discontinuation. Conclusion: The cause of rosacea-like reaction associated with dupilumab treatment is unknown. Th2 pathway inhibition by dupilumab may promote Demodex proliferation and increased IL-17-mediated inflammation implicated in the pathophysiology of rosacea.Abbreviations: atopic dermatitis: AD; interleukin: IL; persistent facial dermatitis: PFD; T-helper cell type 1: Th1; T-helper cell type 2: Th2; T-helper cell type 17: Th17; tumornecrosis factor-∝: TNF-∝.
Authors: Roberto R Ricardo-Gonzalez; Maya E Kotas; Claire E O'Leary; Katelyn Singh; William Damsky; Chang Liao; Elizabeth Arouge; Iliana Tenvooren; Diana M Marquez; Andrew W Schroeder; Jarish N Cohen; Marlys S Fassett; Jinwoo Lee; Scott G Daniel; Kyle Bittinger; Roberto Efraín Díaz; James S Fraser; Niwa Ali; K Mark Ansel; Matthew H Spitzer; Hong-Erh Liang; Richard M Locksley Journal: Immunity Date: 2022-08-30 Impact factor: 43.474
Authors: Ellen Q Wang; Vu Le; Jennifer A Winton; Sakambari Tripathy; Sangeeta Raje; Lisy Wang; Martin E Dowty; Bimal K Malhotra Journal: J Clin Pharmacol Date: 2022-02-15 Impact factor: 2.860